Compare ZETA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZETA | FOLD |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.5B |
| IPO Year | 2021 | 2006 |
| Metric | ZETA | FOLD |
|---|---|---|
| Price | $18.63 | $14.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $27.67 | $27.25 |
| AVG Volume (30 Days) | ★ 7.7M | 2.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.16 | 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,304,668,000.00 | N/A |
| Revenue This Year | $37.35 | $20.50 |
| Revenue Next Year | $16.29 | $18.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.72 | N/A |
| 52 Week Low | $12.10 | $5.66 |
| 52 Week High | $24.90 | $14.50 |
| Indicator | ZETA | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 74.18 |
| Support Level | $17.50 | $14.21 |
| Resistance Level | $19.83 | N/A |
| Average True Range (ATR) | 0.92 | 0.02 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 71.77 | 100.00 |
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing. The company operates in U.S, where it generates maximum revenue and Internationally as well.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.